Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Urinary tract infections,Pyelonephritis,Chronic bacterial prostatitis,Lower respiratory tract infections,Acute sinusitis,Skin and skin structure infections,Bone and joint infections,Complicated intra-abdominal infections,Infectious diarrhea,Typhoid fever,Uncomplicated cervical and urethral gonorrhea,Inhalational anthrax (post-exposure),Plague,Febrile neutropenia (in combination)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
400 mg IV every 8 hours for urinary tract infections; 400 mg IV every 12 hours for other infections. Infuse over 60 minutes.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
3-5 hours in patients with normal renal function (creatinine clearance > 50 m L/min). In severe renal impairment (Cr Cl < 20 m L/min), half-life may extend to 6-8 hours. The terminal elimination half-life reflects the prolonged clearance of the drug from peripheral tissues such as skin and bone.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Partially metabolized in the liver via CYP1A2 to four metabolites (desethylene-, sulfociprofloxacin, oxociprofloxacin, and formylciprofloxacin).
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion. Additionally, about 15% is excreted as metabolites (oxo-ciprofloxacin, desethyleneciprofloxacin, sulfociprofloxacin). Biliary/fecal excretion accounts for 20-35%, primarily as unchanged drug and metabolites, with some enterohepatic recirculation.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
20-40% bound to serum proteins, primarily albumin. Binding is concentration-independent and saturable at high doses ( > 400 mg), but clinically significant displacement interactions are rare due to low affinity.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
2.5-3.0 L/kg. This large Vd indicates extensive tissue penetration with concentrations exceeding serum levels in kidney (2-3x), lung (2-3x), prostate (2x), and bone (1-2x). Penetration into cerebrospinal fluid is low (10-40% of serum levels) in non-inflamed meninges, but increases to 50-90% with inflammation.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% bioavailability (administered as a 0.9% sodium chloride solution). Oral ciprofloxacin bioavailability is 70-80% but is not relevant for this IV formulation.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Cr Cl 30-50 m L/min: 400 mg IV every 18-24 hours. Cr Cl 5-29 m L/min: 400 mg IV every 24 hours. Cr Cl <5 m L/min (on hemodialysis): 400 mg IV every 24 hours (administer after dialysis).
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment for hepatic impairment; systemic exposure may be increased but no dose guidelines established.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Neonates (0-7 days): 10 mg/kg IV every 12 hours. Infants (8-28 days): 10 mg/kg IV every 8 hours. Children (1 month - 5 years): 10 mg/kg IV every 8 hours (max 400 mg/dose). Children (5-17 years): 10 mg/kg IV every 8 hours (max 400 mg/dose) for complicated infections; 6-10 mg/kg IV every 8 hours for uncomplicated infections.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Adjust based on renal function (Cr Cl); no age-specific dose modifications. Monitor for CNS effects and tendon disorders.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, those taking corticosteroids, and patients with kidney, heart, or lung transplants.
None
Tendon damage, including rupture, can occur within hours or up to several months after therapy,Exacerbation of myasthenia gravis symptoms,Peripheral neuropathy that may be irreversible,Central nervous system effects including seizures, dizziness, and increased intracranial pressure,Clostridium difficile-associated diarrhea,Phototoxicity,QT prolongation,Hypersensitivity reactions, including anaphylaxis,Hepatotoxicity,Blood glucose disturbances, including hypoglycemia and hyperglycemia
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to ciprofloxacin or any quinolone,Concomitant administration with tizanidine
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions with IV ciprofloxacin; however, oral absorption is affected by dairy and calcium-fortified juices. For IV form, no dietary restrictions. Avoid excessive caffeine intake as ciprofloxacin may increase its effects.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Ciprofloxacin is generally avoided during pregnancy, especially in the first trimester, due to potential arthropathy in animal studies. Human data do not demonstrate a significant increase in major malformations, but there is a theoretical risk of fetal cartilage damage. Use only if benefit outweighs risk and no safer alternative exists.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Ciprofloxacin is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.85. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific dose adjustment is recommended for pregnancy, but pharmacokinetic changes (increased volume of distribution, renal clearance) may necessitate careful monitoring of clinical response. Use lowest effective dose for shortest duration; intravenous formulation may be preferred in severe infections.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Administer Cipro in Sodium Chloride 0.9% via IV infusion over 60 minutes to reduce risk of infusion site reactions. Monitor for tendonitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with renal impairment. Avoid use in myasthenia gravis due to potential neuromuscular blockade. Dose adjustment required for Cr Cl < 30 m L/min; for Cr Cl 30-50 m L/min, usual dose every 12 hours. Ciprofloxacin can prolong QT interval; monitor ECG if concomitant with other QT-prolonging drugs or in patients with electrolyte abnormalities.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously; you will receive it over at least 60 minutes.,Notify your healthcare provider immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon).,Report any signs of nerve damage such as pain, burning, tingling, numbness, or weakness.,Avoid excessive sun exposure or use sunscreen, as this drug may increase photosensitivity.,Inform your doctor if you have a history of seizures, QT prolongation, or myasthenia gravis.,Stay well hydrated unless otherwise instructed by your doctor.,Do not abruptly stop this medication without consulting your doctor.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 400 mg IV every 8 hours for urinary tract infections; 400 mg IV every 12 hours for other infections. Infuse over 60 minutes.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Ciprofloxacin is generally avoided during pregnancy, especially in the first trimester, due to potential arthropathy in animal studies. Human data do not demonstrate a significant . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.